Download PDF
Dialyse aktuell 2018; 22(07): 312-316
DOI: 10.1055/a-0669-8909
Schwerpunkt | Transplantation
© Georg Thieme Verlag KG Stuttgart · New York

Immunsuppression beim nierentransplantierten Patienten über 65 Lebensjahre

Adjustierung nach immunologischem Risiko und Spenderorganqualität
Alexander Reshetnik
Klinik für Nephrologie, Charité – Universitätsmedizin Berlin, Kooperationspartner der Freien Universität Berlin, Humboldt-Universität zu Berlin, und des Berliner Instituts für Gesundheitsforschung
› Author Affiliations
Further Information

Publication History

Publication Date:
10 September 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Ältere Patienten stellen eine zunehmende Population unter den Transplantierten. Leider sind die empirischen Daten zur immunsuppressiven Therapie in diesem Kollektiv bislang begrenzt. Die vorhandene Evidenz deutet jedoch darauf hin, dass verfügbare moderne Immunsuppressionsprotokolle unter Beachtung spezieller Besonderheiten bei älteren Patienten auch in dieser Klientel problemlos eingesetzt werden können. Dennoch sollten zukünftige randomisierte Studien ältere Empfänger einschließen, um die Empirik in dieser zunehmend größeren Population zu erweitern.

 

  • Literatur

  • 1 Pippias M, Jager KJ, Kramer A. et al. The changing trends and outcomes in renal replacement therapy: data from the ERA-EDTA Registry. Nephrol Dial Transplant 2016; 31: 831-841 doi: 10.1093/ndt/gfv327
    CrossrefPubMedGoogle Scholar
  • 2 Rao PS, Merion RM, Ashby VB. et al. Renal transplantation in elderly patients older than 70 years of age: results from the Scientific Registry of Transplant Recipients. Transplantation 2007; 83: 1069-1074 doi: 10.1097/01.tp.0000259621.56861.31
    CrossrefPubMedGoogle Scholar
  • 3 Perlman RL, Rao PS. Quality of life of older patients undergoing renal transplantation: finding the right immunosuppressive treatment. Drugs Aging 2014; 31: 103-109 doi: 10.1007/s40266–013–0149-x
    CrossrefPubMedGoogle Scholar
  • 4 Schold JD, Meier-Kriesche HU. Which renal transplant candidates should accept marginal kidneys in exchange for a shorter waiting time on dialysis?. Clin J Am Soc Nephrol 2006; 1: 532-538 doi: 10.2215/CJN.01130905
    CrossrefPubMedGoogle Scholar
  • 5 Ponticelli C, Podesta MA, Graziani G. Renal transplantation in elderly patients. How to select the candidates to the waiting list?. Transplant Rev (Orlando) 2014; 28: 188-192 doi: 10.1016/j.trre.2014.07.001
    CrossrefPubMedGoogle Scholar
  • 6 Watt KD, Pedersen RA, Kremers WK. et al. Long-term probability of and mortality from de novo malignancy after liver transplantation. Gastroenterology 2009; 137: 2010-2017 doi: 10.1053/j.gastro.2009.08.070
    CrossrefPubMedGoogle Scholar
  • 7 Fulop T, Larbi A, Witkowski JM. et al. Immunosenescence and cancer. Crit Rev Oncog 2013; 18: 489-513 doi: 10.1615/CritRevOncog.2013010597
    CrossrefPubMedGoogle Scholar
  • 8 Saule P, Trauet J, Dutriez V. et al. Accumulation of memory T cells from childhood to old age: central and effector memory cells in CD4(+) versus effector memory and terminally differentiated memory cells in CD8(+) compartment. Mech Ageing Dev 2006; 127: 274-281 doi: 10.1016/j.mad.2005.11.001
    CrossrefPubMedGoogle Scholar
  • 9 Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des 2013; 19: 1680-1698 doi: 10.2174/​1381612811319090016
    PubMedGoogle Scholar
  • 10 Frasca D, Diaz A, Romero M. et al. Age effects on B cells and humoral immunity in humans. Ageing Res Rev 2011; 10: 330-335 doi: 10.1016/j.arr.2010.08.004
    CrossrefGoogle Scholar
  • 11 Shao M, Wan Q, Xie W. et al. Bloodstream infections among solid organ transplant recipients: epidemiology, microbiology, associated risk factors for morbility and mortality. Transplant Rev (Orlando) 2014; 28: 176-181 doi: 10.1016/j.trre.2014.02.001
    CrossrefPubMedGoogle Scholar
  • 12 Le Page AK, Mackie FE, McTaggart SJ. et al. Cytomegalovirus & Epstein Barr Virus serostatus as a predictor of the long-term outcome of kidney transplantation. Nephrology (Carlton) 2013; 18: 813-819 doi: 10.1111/nep.12149
    CrossrefPubMedGoogle Scholar
  • 13 Ok Atilgan A, Ozdemir BH, Kirnap M. et al. Invasive fungal infections in liver transplant recipients. Exp Clin Transplant 2014; 12 (Suppl. 01) 110-116
    PubMedGoogle Scholar
  • 14 Peev V, Reiser J, Alachkar N. Diabetes mellitus in the transplanted kidney. Front Endocrinol (Lausanne) 2014; 5: 141 doi: 10.3389/fendo.2014.00141
    Google Scholar
  • 15 Tullius SG, Milford E. Kidney allocation and the aging immune response. N Engl J Med 2011; 364: 1369-1370 ​doi: 10.1056/NEJMc1103007
    CrossrefPubMedGoogle Scholar
  • 16 Frei U, Noeldeke J, Machold-Fabrizii V. et al. Prospective age-matching in elderly kidney transplant recipients – ​a 5-year analysis of the Eurotransplant Senior Program. Am J Transplant 2008; 8: 50-57 doi: 10.1111/j.1600–6143.2007.02014.x
    PubMedGoogle Scholar
  • 17 Jacobson PA, Schladt D, Oetting WS. et al. Lower calcineurin inhibitor doses in older compared to younger kidney transplant recipients yield similar troughs. Am J Transplant 2012; 12: 3326-3336 doi; 10.1111/j.1600–6143.2012.04232.x
    CrossrefPubMedGoogle Scholar
  • 18 George J, Byth K, Farrell GC. Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 1995; 50: 727-730 doi: 10.1016/0006–2952(95)00192–3
    CrossrefPubMedGoogle Scholar
  • 19 Zahir H, McCaughan G, Gleeson M. et al. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol 2004; 57: 298-309 10.1046/j.1365–2125.2003.02008.x
    PubMedGoogle Scholar
  • 20 Shah T, Kasravi A, Huang E. et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006; 82: 1673-1676 doi: 10.1097/01.tp.0000250756.66348.9a
    CrossrefPubMedGoogle Scholar
  • 21 Pahlavani MA, Vargas DM. Influence of aging and caloric restriction on activation of Ras/MAPK, calcineurin, and CaMK-IV activities in rat T cells. Proc Soc Exp Biol Med 2000; 223: 163-169 doi: 10.1111/j.1525–1373.2000.22322.x
    CrossrefPubMedGoogle Scholar
  • 22 Whisler RL, Beiqing L, Chen M. Age-related decreases in IL-2 production by human T cells are associated with impaired activation of nuclear transcriptional factors AP-1 and NF-AT. Cell Immunol 1996; 169: 185-195 doi: 10.1111/j.2040–1124.2010.00046.x
    CrossrefPubMedGoogle Scholar
  • 23 Kauffman HM, Cherikh WS, Cheng Y. et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889 doi: 10.1097/01.TP.0000184006.43152.8D
    CrossrefPubMedGoogle Scholar
  • 24 Zimmerman JJ, Lasseter KC, Lim HK. et al. Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment. J Clin Pharmacol 2005; 45: 1368-1372 doi: 10.1177/0091270005281350
    CrossrefPubMedGoogle Scholar
  • 25 Kovarik JM, Sabia HD, Figueiredo J. et al. Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment. Clin Pharmacol Ther 2001; 70: 425-430 doi: 10.1016/S0009–9236(01)15633-X
    CrossrefGoogle Scholar
  • 26 Tredger JM, Brown NW, Adams J. et al. Monitoring mycophenolate in liver transplant recipients: toward a therapeutic range. Liver Transpl 2004; 10: 492-502 doi: 10.1002/lt.20124
    CrossrefPubMedGoogle Scholar
  • 27 Stuck AE, Frey BM, Frey FJ. Kinetics of prednisolone and endogenous cortisol suppression in the elderly. Clin Pharmacol Ther 1988; 43: 354-562 doi: 10.1038/clpt.1988.43
    CrossrefPubMedGoogle Scholar
  • 28 Tornatore KM, Logue G, Venuto RC. et al. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J Clin Pharmacol 1997; 37: 304-311 doi: 10.1002/j.1552–4604.1997.tb04307.x
    CrossrefPubMedGoogle Scholar
  • 29 Kawai S, Ichikawa Y, Homma M. Differences in metabolic properties among cortisol, prednisolone, and dexamethasone in liver and renal diseases: accelerated metabolism of dexamethasone in renal failure. J Clin Endocrinol Metab 1985; 60: 848-854 doi: 10.1210/jcem-60–5–848
    CrossrefPubMedGoogle Scholar
  • 30 Lebrun-Vignes B, Archer VC, Diquet B. et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51: 443-450 doi: 10.1046/j.1365–2125.2001.01372.x
    CrossrefPubMedGoogle Scholar
  • 31 Penfornis A, Kury-Paulin S. Immunosuppressive drug-induced diabetes. Diabetes Metab 2006; 32 (05) Pt 2 539-546 doi: 10.1016/S1262–3636(06)72809–9
    CrossrefPubMedGoogle Scholar
  • 32 Zhou Z, Shen J, Hong Y. et al. Time-varying belatacept exposure and its relationship to efficacy/safety responses in kidney-transplant recipients. Clin Pharmacol Ther 2012; 92: 251-257 doi: 10.1038/clpt.2012.84
    CrossrefGoogle Scholar
  • 33 Agrawal A, Agrawal S, Cao JN. et al. Altered innate immune functioning of dendritic cells in elderly humans: a role of phosphoinositide 3-kinase-signaling pathway. J Immunol 2007; 178: 6912-6922 doi: 10.4049/jimmunol.178.11.6912
    CrossrefPubMedGoogle Scholar
  • 34 Masson P, Henderson L, Chapman JR. et al. Belatacept for kidney transplant recipients. Cochrane Database Syst Rev 2014; CD010699 doi: 10.1002/14651858.CD010699.pub2
    Google Scholar
  • 35 Mahbub S, Deburghgraeve CR, Kovacs EJ. Advanced age impairs macrophage polarization. J Interferon Cytokine Res 2012; 32: 18-26 doi: 10.1089/jir.2011.0058
    CrossrefPubMedGoogle Scholar
  • 36 Steinebrunner N, Sandig C, Sommerer C. et al. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes – a prospective study. Ann Transplant 2014; 19: 32-40 doi: 10.12659/AOT.889809
    CrossrefPubMedGoogle Scholar
  • 37 Leogrande D, Teutonico A, Ranieri E. et al. Monitoring biological action of rapamycin in renal transplantation. Am J Kidney Dis 2007; 50: 314-325 doi: 10.1053/j.ajkd.2007.05.002
    CrossrefPubMedGoogle Scholar
  • 38 Gill J, Sampaio M, Gill JS. et al. Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol 2011; 6: 1168-1178 doi: 10.2215/CJN.07540810
    CrossrefPubMedGoogle Scholar
  • 39 Patel SJ, Knight RJ, Suki WN. et al. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant 2011; 25: E250-E256 doi: 10.1111/j.1399–0012.2010.01393.x
    CrossrefPubMedGoogle Scholar
  • 40 Woodle ES, First MR, Pirsch J. et al. Astellas Corticosteroid Withdrawal Study G. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577 doi: 10.1097/SLA.0b013e318187d1da
    PubMedGoogle Scholar
  • 41 Badowski M, Gurk-Turner C, Cangro C. et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant 2009; 23: 930-937 doi: 10.1111/j.1399–0012.2009.01028.x
    CrossrefPubMedGoogle Scholar
  • 42 Krenzien F, ElKhal A, Quante M. et al. A rationale for age-adapted immunosuppression in organ transplantation. Transplantation 2015; 99: 2258-2268 doi: 10.1097/TP.0000000000000842
    CrossrefPubMedGoogle Scholar
  • 1 Keller F. Professor Doktor Hans-Eduard Franz 80 Jahre. Nieren Hochdruckkrh 2008; 37: 157
    Google Scholar